Immunovant (IMVT) vs Iovance Biotherapeutics (IOVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Immunovant (IMVT) over the past year, gaining 486.3% versus a gain of 88.2%. Over five years, IMVT leads with a +247.0% price change compared with -50.0% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($6.62 billion vs $6.29 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | IOVA |
|---|---|---|
| Share price | $30.47 | $14.62 |
| Market cap | $6.29B | $6.62B |
| 1-day change | +0.69% | +9.84% |
| YTD return | +19.04% | +387.55% |
| 1-year return | +88.24% | +486.34% |
| 5-year return | +247.02% | -49.98% |
| EPS (TTM) | $-2.82 | $-0.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $263.50M |
| Revenue growth (YoY) | — | +60.60% |
| Net income (latest FY) | $-505.61M | $-390.98M |
| Gross margin | — | 34.28% |
| Operating margin | — | -153.08% |
| Net margin | — | -148.38% |
| 52-week high | $45.42 | $15.30 |
| 52-week low | $16.60 | $1.76 |
| Distance from 52-week high | -32.92% | -4.44% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +60.42% | -12.45% |
| Average volume | 1.24M | 17.82M |
| Shares outstanding | 206.55M | 452.97M |
| Employees | 315 | 975 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed IMVT by 398.1 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
IMVT vs IOVA FAQ
Which is bigger, Immunovant or Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $6.62B compared with $6.29B for Immunovant (IMVT).
Which stock has performed better over the past year, IMVT or IOVA?
IOVA returned +486.34% over the past 12 months, compared with +88.24% for IMVT (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Iovance Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.